Bristol Myers Squibb Company $BMY Stake Cut by United Advisor Group LLC

United Advisor Group LLC trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 33.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,796 shares of the biopharmaceutical company’s stock after selling 9,428 shares during the period. United Advisor Group LLC’s holdings in Bristol Myers Squibb were worth $1,173,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. raised its position in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp lifted its holdings in Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Primecap Management Co. CA purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after purchasing an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock worth $1,137,847,000 after purchasing an additional 520,330 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BMY shares. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 19th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Truist Financial set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, October 30th. The Goldman Sachs Group raised shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Friday, October 16th. Finally, Daiwa Securities Group lifted their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $65.46.

Bristol Myers Squibb Stock Down 1.5%

Bristol Myers Squibb stock opened at $62.20 on Friday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The firm has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The stock’s fifty day moving average is $62.34 and its two-hundred day moving average is $60.11.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the previous year, the company posted $1.63 EPS. The business’s revenue was up 6.9% on a year-over-year basis. Analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.88%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Julia A. Haller sold 3,800 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.